Yu-Sheng Chao
Yu-Sheng Chao, Monmouth Junction, NJ US
Patent application number | Description | Published |
---|---|---|
20090275533 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS - Fused bicyclic pyrimidine compounds of formula (I): | 11-05-2009 |
20090312317 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER - Coumarin compounds of formula (I): | 12-17-2009 |
20090312406 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I): | 12-17-2009 |
20100081675 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS - Fused multicyclic compounds of formula (I): | 04-01-2010 |
20100113546 | Imidazol-4-one and Imidazole-4-thione Compounds - Imidazol-4-one or imidazole-4-thione compounds of formula (I): | 05-06-2010 |
20100120805 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors - Fused bicyclic or tricyclic compounds of formula (I): | 05-13-2010 |
20110136799 | PROLINE DERIVATIVES - Compounds of formula (I): | 06-09-2011 |
20110172261 | DIBENZO[f,h]ISOQUINOLINE DERIVATIVES - A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection. | 07-14-2011 |
Yu-Sheng Chao, Zhunan Town TW
Patent application number | Description | Published |
---|---|---|
20090155854 | METHOD FOR AMPLIFYING A FLAVIVIRUS cDNA IN A PROKARYOTIC CELL - The invention relates to a method for amplifying a functional flavivirus cDNA in a prokaryotic cell, such as | 06-18-2009 |
Yu-Sheng Chao, Taipei TW
Patent application number | Description | Published |
---|---|---|
20090149545 | TREATMENT OF CORONAVIRUS INFECTION - A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine, thioridazine, chlorprothixene, thiothixene, clozapine, haloperidol, haloperidol decanoate, loxapine, molindone, olanzapine, pimozide, quetiapine, risperidone, and amitriptyline. | 06-11-2009 |
Yu-Sheng Chao, New York, NY US
Patent application number | Description | Published |
---|---|---|
20110263620 | QUINOLINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - Quinoline compounds of formula (I): | 10-27-2011 |
20120046238 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I): | 02-23-2012 |
20120225880 | PYRAZOLE COMPOUNDS AND THIAZOLE COMPOUNDS AS PROTEIN KINASES INHIBITORS - A compound of formula (I): | 09-06-2012 |
20130085126 | PYRAZOLE COMPOUNDS - Compounds of formula (I): | 04-04-2013 |
20130157970 | NOVEL GLYCOSIDE COMPOUNDS - Compounds of formula (I): | 06-20-2013 |
20140127158 | COMBINATION THERAPY FOR HEPATITIS C VIRUS INFECTION - A method of treating hepatitis C virus infection, comprising administering to a subject in need thereof (a) an effective amount of at least one HCV inhibitor selected from the group consisting of an HCV NS3 inhibitor, an HCV NS5B inhibitor, ribavirin, and an IFN-α; and (b) an effective amount of an anti-HCV compound of formula (I). | 05-08-2014 |